Australian pharmacists recognised at 2020 Virtual FIP Congress

Media Release

Australian Pharmacy has been well represented at the virtual International Pharmaceutical Federation (FIP) congress, with University of Sydney School of Pharmacy Professor of Medicines Use Optimisation Parisa Aslani elected as one of three new Vice Presidents of FIP.

Along with Professor Aslani’s appointment, Monash University’s Faculty of Pharmacy and Pharmaceutical Sciences Dean, Professor Bill Charman was named as the winner of the inaugural Kamal K. Midha Award for Exceptional Leadership.

Professor Charman was also one of eight pharmacists and pharmaceutical scientists to be made an FIP Fellow during the opening ceremony.

PSA National President Associate Professor Chris Freeman congratulated Professor Aslani on her significant appointment.

“It is great to see Australian pharmacy being represented on the world stage by exceptional pharmacists like Professor Aslani,” he says.

“The honour of being named Vice President of the FIP follows significant dedication and leadership at the highest levels and presents great opportunity to better connect Australian pharmacy practice to the rest of the world.”

A/Prof Freeman also recognised the achievement of Professor Charman in not only winning the inaugural Kamal K. Midha award but being made an FIP Fellow.

“An FIP Fellowship recognises individual members of FIP who have exhibited strong leadership internationally and distinguished themselves in pharmacy practice or the pharmaceutical sciences,” he says.

“To also receive the very first Kamal K. Midha Award shows Professor Charman’s significant service and leadership in advancing the pharmacy profession.”

Professor Ross McKinnon from Australia was also named as the new chair of the Board of Pharmaceutical Sciences.

Text by: Pharmaceutical Society of Australia

Must Read

Calls for more holistic management of epilepsy

0
Researchers from the Australian Epilepsy Project (AEP) at The Florey are calling for changes to the way epilepsy is managed after a preliminary study highlighted differences...

TB funding vital